Supplementary Table S4 from Combination of an Autoantibody Panel and Alpha-Fetoprotein for Early Detection of Hepatitis B Virus-Associated Hepatocellular Carcinoma

Supplementary Table S4: The AUC of these four TAAbs for identifying HBV-HCC patients from CHB patients ranged from 0.693-0.739. Among them, anti-DUSP6 showed the highest diagnostic ability, with an AUC of 0.739 (95% CI [confidence interval]: 0.694-0.785). The diagnostic capability of anti-PCNA was the poorest, with an AUC of 0.693 (95% CI: 0.645-0.741). The AUC of four candidate TAAbs in differentiating between HBV-HCC and HBV-LC patients ranged from 0.589 to 0.624. Among them, anti-PCNA had the most diagnostic capacity, with an AUC of 0.624 (95% CI: 0.569-0.679). Anti-CDC37L1 had the least diagnostic capability, with an AUC of 0.589 (95% CI: 0.533-0.645).